{"id":"W2086621090","doi":"10.1097/spc.0b013e32832e469d","title":"Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?","year":2009,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Sunitinib; Everolimus; Bevacizumab; Renal cell carcinoma; Oncology; Internal medicine; Cabozantinib; Tyrosine-kinase inhibitor; First line; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001016499,0.0005853036,0.003580551,0.0009930539,0.0001967942,0.0009343966,0.0008307599,0.001210095,0.003289348],"category_scores_gemma":[0.002075916,0.0002099463,0.0007731827,0.001451062,0.000399966,0.001526725,0.0002381629,0.001289264,0.00157546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005262031,"about_ca_system_score_gemma":0.00123192,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001275514,"about_ca_topic_score_gemma":0.002689414,"domain_scores_codex":[0.9996786,0.0000943678,0.00006368259,0.00004354903,0.00009754467,0.0000222075],"domain_scores_gemma":[0.9990895,0.0005338295,0.0001701837,0.0000168867,0.0001488525,0.00004069549],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001452123,0.00005312535,0.0003400676,0.05642531,0.0002367294,0.0004133309,0.00007746245,0.0002813914,0.0005403629,0.001084682,0.03273971,0.9076625],"study_design_scores_gemma":[0.0002004448,0.0003474047,0.004779332,0.05421189,0.001048506,0.007912499,0.0004172474,0.0002525697,0.0007415297,0.002606742,0.9274261,0.0000557541],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001242545,0.9988487,0.00004274921,0.0004211851,0.0002048658,0.000003194788,0.000009820202,0.000002853378,0.0003423418],"genre_scores_gemma":[0.000965693,0.9980527,0.0001170792,0.0003529819,0.0002217495,0.000004989886,0.00002143449,0.000001289446,0.0002620351],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003580551,"threshold_uncertainty_score":0.01100397,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1010475551081741,"score_gpt":0.3912191576438094,"score_spread":0.2901716025356353,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}